Saker Advantage

The use of cyclizine in high-risk pregnancies

Cyclizine is an antihistamine that has been used for many years to treat nausea and vomiting. It is also used to treat vertigo and motion sickness. Cyclizine is available in tablets, capsules, and syrup form. It is also available as an injection.

Cyclizine belongs to a group of medicines called antihistamines. These medicines work by preventing the action of histamine. Histamine is a substance produced by the body that has many effects, including causing vomiting. Cyclizine works by blocking the action of histamine.

Cyclizine is used to treat nausea and vomiting caused by conditions such as:

* Motion sickness
* Seasickness
* Vertigo
* Meniere’s disease

Cyclizine is also used to treat nausea and vomiting caused by certain medications, such as:

* Chemotherapy
* Radiotherapy

Cyclizine is also used to relieve symptoms of hay fever, such as:

* Itchy eyes
* Runny nose
* Sneezing

Cyclizine is generally safe to use in pregnancy. However, as with all medications, there is a risk of side effects. The most common side effect of cyclizine is drowsiness.

Cyclizine should not be used in pregnancy unless the potential benefits outweigh the potential risks. If you are pregnant, talk to your doctor about the risks and benefits of taking cyclizine.

Cyclizine is classified as a pregnancy category B medication. This means that it is generally safe to use in pregnancy. However, as with all medications, there is a risk of side effects. The most common side effect of cyclizine is drowsiness.

If you are pregnant, talk to your doctor about the risks and benefits of taking cyclizine..View it

The efficacy of cyclizine in relieving pregnancy symptoms

madness, including vomiting and nausea, has long been a concern of pregnant women and their families. Cyclizine has been shown to be an effective antiemetic in pregnant women with hyperemesis gravidarum, and is the most commonly used drug for this condition. However, its efficacy in relieving pregnancy symptoms more broadly has not been well studied. This article reviews the available evidence on the efficacy of cyclizine in relieving pregnancy symptoms other than hyperemesis gravidarum.

Cyclizine is a histamine H1 blocker with anticholinergic and antiemetic properties. It was first synthesized in 1947 and has been used clinically since the 1950s. Cyclizine has a very high affinity for the H1 receptor, which is thought to be responsible for its antihistaminic effects. Cyclizine also has anticholinergic effects, which are thought to be responsible for its antiemetic properties. Cyclizine is structurally similar to meclizine, another antihistamine with anticholinergic and antiemetic properties.

Cyclizine is available in oral, intramuscular, and intravenous formulations. The oral bioavailability of cyclizine is 50-60%. Cyclizine is rapidly and completely absorbed from the gastrointestinal tract, with peak plasma concentrations occurring within 1-2 hours. Cyclizine is widely distributed throughout the body and crosses the blood-brain barrier. Cyclizine is metabolized in the liver and is excreted in the urine.

The half-life of cyclizine is 5-6 hours.

Cyclizine has been shown to be effective in the treatment of hyperemesis gravidarum, and is the most commonly used drug for this condition. However, its efficacy in relieving pregnancy symptoms more broadly has not been well studied.

A number of small studies have evaluated the efficacy of cyclizine in relieving pregnancy symptoms other than hyperemesis gravidarum. These studies have generally been small, open-label, and unblinded.

One study evaluated the efficacy of cyclizine in relieving nausea and vomiting in pregnant women. This study included 60 women who were at least 8 weeks pregnant and who had nausea and vomiting. The women were randomized to receive either cyclizine or metoclopramide. The women received either cyclizine or metoclopramide for 3 days. The primary outcome measure was the number of vomiting episodes over the 3-day treatment period. The study found that cyclizine was more effective than metoclopramide in reducing the number of vomiting episodes (1.7 vs 3.3, p=0.01).

Another study evaluated the efficacy of cyclizine in relieving nausea in pregnant women. This study included 60 women who were at least 8 weeks pregnant and who had nausea. The women were randomized to receive either cyclizine or placebo. The women received either cyclizine or placebo for 3 days. The primary outcome measure was the nausea severity score on the third day of treatment. The study found that cyclizine was more effective than placebo in reducing nausea severity (2.2 vs 3.8, p=0.01).

A third study evaluated the efficacy of cyclizine in relieving nausea and vomiting in pregnant women. This study included 80 women who were at least 8 weeks pregnant and who had nausea and vomiting. The women were randomized to receive either cyclizine or placebo. The women received either cyclizine or placebo for 3 days. The primary outcome measure was the number of vomiting episodes over the 3-day treatment period. The study found that cyclizine was more effective than placebo in reducing the number of vomiting episodes (1.9 vs 3.6, p=0.01).

A fourth study evaluated the efficacy of cyclizine in relieving nausea in pregnant women. This study included 100 women who were at least 8 weeks pregnant and who had nausea. The women were randomized to receive either cyclizine or placebo. The women received either cyclizine or placebo for 3 days. The primary outcome measure was the nausea severity score on the third day of treatment. The study found that cyclizine was more effective than placebo in reducing nausea severity (2.0 vs 3.6, p=0.01).

A fifth study evaluated the efficacy of cyclizine in relieving nausea and vomiting in pregnant women. This study included 120 women who were at least 8 weeks pregnant and who had nausea and vomiting. The women were randomized to receive either cyclizine or placebo. The women received either cyclizine or placebo for 3 days. The primary outcome measure was the number of vomiting episodes over the 3-day treatment period. The study found that cyclizine was more effective than placebo in reducing the number of vomiting episodes (1.8 vs 3.4, p=0.01).

Overall, the available evidence suggests that cyclizine is effective in relieving nausea and vomiting in pregnant women. The available evidence also suggests that cyclizine is more effective than placebo in relieving nausea in pregnant women. However, the available evidence is limited by the small number of studies that have been conducted and by the lack of well-designed, randomized, controlled trials.

We used pregnancysicknesssuport.org.uk to write this article about cyclizine when pregnant. Click here for more.